Programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) expression, immunotherapy, and their outcomes in LCNEC open a new door for considering a new standard treatment [27–31]. This evidence concerns the gene CD274 and large cell neuroendocrine carcinoma.